Affiliation:
1. Research Group on Community Nutrition and Oxidative Stress, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain
Abstract
Background:
Several drugs have been currently approved for the treatment of obesity. The pharmacokinetic
of liraglutide, as well as the treatment of type 2 diabetes mellitus, have been widely described.
Objective:
To analyze the published systematic reviews on the use of liraglutide for the treatment of obesity.
Methods:
Systematic reviews were found out through MEDLINE searches, through EBSCO host and the Cochrane
Library based on the following terms: "liraglutide" as major term and using the following Medical Subject
Headings (MesH) terms: "obesity", "overweight", "weight loss". A total of 3 systematic reviews were finally
included to be analyzed.
Results:
From the three systematic reviews selected, only two included the randomized clinical trials, while the
third study reviewed both randomized and non-randomized clinical trials. Only one review performed statistical
tests of heterogeneity and a meta-analysis, combining the results of individual studies. Another review showed
the results of individual studies with odds ratio and confidence interval, but a second one just showed the means
and confidence intervals. In all studies, weight loss was registered in persons treated with liraglutide in a dose
dependent form, reaching a plateau at 3.0 mg dose, which was reached just in men. Most usual adverse events
were gastrointestinal.
Conclusion:
More powerful and prospective studies are needed to assess all aspects related to liraglutide in the
overweight and obesity treatment.
Funder
European Regional Development Fund; EU-COST Action
Instituto de Salud Carlos III
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Reference25 articles.
1. Martín J.; Martín A.; Epidemiología de la obesidad Análisis de determinantes dietéticos y de actividad físicaObesidad en el siglo XXI: ¿Qué se puede y qué se debe hacer? 2009,27-33
2. González Jiménez E.; [Body composition: Assessment and clinical
value]. Endocrinol Nutr [PMID: 22704270].2013,60(2),69-75
3. Rubio M.; Salas-Salvadó J.; Barbany M.; Consenso de la Sociedad Española para el Estudio de la Obesidad (SEEDO) 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Rev Esp Obes 2007,128(5),7-48
4. Rothman K.J.; BMI-related errors in the measurement of obesity. Int J Obes [http://dx.doi.org/10.1038/ijo.2008.87]. [PMID: 18695655].2008,32(Suppl. 3),S56-S59
5. Pasanisi F.; Contaldo F.; de Simone G.; Mancini M.; Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis [PMID: 12055705].2001,11(6),401-406
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献